GeoVax Advances Toward European Approval for Mpox Vaccine Following EMA Guidance

GeoVax Labs, Inc. has highlighted a significant regulatory milestone with the European Medicines Agency (EMA) providing positive Scientific Advice for its GEO-MVA vaccine aimed at combating Mpox and smallpox. This advice suggests that a single Phase 3 immuno-bridging trial could suffice for a Marketing Authorization Application (MAA) in the EU, bypassing earlier phase trials and significantly reducing development time and risk.

The EMA's guidance positions GeoVax for an expedited approval process in one of the world's largest vaccine markets, aligning with global demand and regulatory momentum. The company is preparing for a Phase 3 trial in the latter half of 2026, with current manufacturing capabilities ready to support near-term supply needs. This development not only de-risks the vaccine's path to market but also enhances GeoVax's strategic value as it transitions towards becoming a commercial vaccine company.

David Dodd, Chairman and CEO of GeoVax, emphasized the commercial inflection point this EMA guidance represents, highlighting the potential for accelerated revenue generation and the company's readiness to meet global supply demands. With the GEO-MVA vaccine, GeoVax aims to provide an alternative to the current monopolistic market, addressing critical public health needs and offering a first-mover advantage in the Mpox vaccine space.